FUJIFILM Wako Chemicals Europe GmbH +49-2131-311-0 info_wkeu@fujifilm.com

FUJIFILM Wako Beta-Glucan Test in 2020: Overview of 5 important publications

In 2020 various researchers in Europe published their study results on the FUJIFILM Wako Beta-Glucan Test. In the following article we would like to present five publications in chronological order.

“Prospective Evaluation of the Turbidimetric β-D-Glucan Assay and 2 Lateral Flow Assays on Serum in Invasive Aspergillosis” by T. Mercier et al.:

The lateral flow assay (LFA), the lateral flow device (LFD) and the single beta-Glucan test by FUJIFILM Wako were evaluated using serum samples from 239 hematology patients. The authors concluded that the combination of the LFA with the FUJIFILM Wako beta-Glucan Test yielded the highest calculated negative predictive value (NPV) in this study.

For further information about this publication in the journal Clinical Infectious Diseases please follow this link: https://doi.org/10.1093/cid/ciaa295

 

“Comparative performance evaluation of Wako β-glucan test and Fungitell assay for the diagnosis of invasive fungal diseases” by E. De Carolis et al.:

The authors conducted a retrospective performance assessment study about 1,3-β-D-glucan (BDG), a well-known invasive fungal disease biomarker. In this study, two BDG tests including our Wako β-Glucan Test were compared to diagnose invasive Aspergillosis (IA), invasive Candidiasis (IC) and Pneumocystis jirovecii pneumonia (PJP). When an optimized cut-off value of 7.0 pg/mL for the Wako β-Glucan Test was used, the sensitivity and specificity were 80.0% and 97.3% for IA diagnosis, 98.7% and 97.3% for IC diagnosis, and 94.1% and 97.3% for PJP diagnosis, respectively.

For further information about this publication in the journal PLOS ONE please follow this link: https://doi.org/10.1371/journal.pone.0236095

 

“Quantification of 1,3‐β‐d‐glucan by Wako β‐glucan assay for rapid exclusion of invasive fungal infections in critical patients: A diagnostic test accuracy study” by Cento et al.:

To investigate the diagnostic performance of the Wako β-Glucan Test this study focused on the optimization of the β-D-Glucan (BDG) cut-off values for invasive fungal infection (IFI) exclusion. Rapid and reliable exclusion of IFI by markers like BDG, able to avoid unnecessary empirical antifungal treatment is still a critical unmet clinical need. The authors concluded a promising diagnostic approach using the Wako β-Glucan Test.

For further information about this publication in the journal Mycoses please follow this link to the Wiley Online Library: https://doi.org/10.1111/myc.13170

 

“Comparison of β-D-Glucan and Galactomannan in Serum for Detection of Invasive Aspergillosis: Retrospective Analysis with Focus on Early Diagnosis” by Dichtl et al.:

This study compared the detection of the established ELISA based galactomannan (GM) with the turbidimetric assay for the detection of β-D-glucan (BDG) for early diagnosis of Invasive Aspergillosis (IA) in 226 sera including proven and probable IA cases. Diagnostic sensitivities were calculated in samples obtained closest to the day of IA-diagnosis and additionally during the presumed course of disease. The sensitivity of BDG testing was as high as or even higher than GM testing in all analyses, the specificity was lower. A combination of both tests to improve the overall sensitivity is suggested.

For further information about this publication in the Journal of Fungi please follow this link to MDPI: https://doi.org/10.3390/jof6040253

 

“Clinical evaluation of two different (1,3)‐β‐d‐glucan assays for diagnosis of invasive fungal diseases: A retrospective cohort study” by Zubkowicz and Held et al.:

The aim of this retrospective cohort study was to evaluate the diagnostic performance of the fungal biomarker (1,3)‐β‐d‐glucan (BDG) in real‐life clinical practice. The authors concluded that a positive test result of both BDG assays at manufacturer's cut‐off was highly predictive for invasive fungal diseases (IFD, 89.5%‐98.3%), but except for Pneumocystis jirovecii pneumonia sensitivities were limited. Reducing the cut‐off value in the FUJIFILM Wako test from 11.0 to 4.1 pg/ml increased the detection rate of IFDs and equalised sensitivities of both BDG assays.

For further information about this publication in the journal Mycoses please follow this link to the Wiley Online Library: https://doi.org/10.1111/myc.13207

 

If you would like to learn more about FUJIFILM Wako's β-Glucan Test, please download the β-Glucan Test Flyer here.

Related products

Beta-Glucan Test
The Toxinometer MT-6500 based β-Glucan Test is an  in vitro  diagnostic test for the quantitative determination of (1→3)-β-D-glucan in serum or plasma. The assay is based on LAL (Limulus Amebocyte lysate) cascade...
Toxinometer MT-6500
The Toxinometer MT-6500 and the related equipment are proprietary devices developed by FUJIFILM Wako Pure Chemical Corporation. These devices are used for the quantitative measurement of (1→3)-β-D-glucan by a kinetic...
Englisch